Abstract: An immunotherapy method of targeted chemokine and cytokine delivery by a mesenchymal stem cell that expresses an immunostimulatory factor. The immunostimulatory factor is selected from the following group: CCL3, CCL19, CCL21, XCL1, CXCL9, OX40L, 4-1BBL, GITRL, CD40L, or a combination thereof. At a tumor site, the mesenchymal stem cell specifically attracts and activates an immune cell that kills tumor tissue, and the mesenchymal stem cell has a synergistic effect with chemokines and/or cytokines, having an immunotherapeutic effect with higher efficiency and few side effects, and a significantly enhanced ability to kill tumor tissue, especially colorectal cancer cells.

Abstract: An assistive fitness system, assistive fitness method, and fitness equipment are provided. The assistive fitness system includes a thermal imaging device configured to receive an infrared signal from a human body and perform thermal imaging processing based on the infrared signal to generate a human body image; a comparing device configured to compare the human body image with a reference image of a standard fitness movement to generate a comparison result; and a display device configured to display the human body image and the comparison result of the human body image and the reference image.

Abstract: Systems, methods, and apparatus are provided for intelligent cybersecurity processing of a product update. A fetcher application may access an updated version of a software product, a prior version of the product, and a version control system for the product. A malicious software identification engine may process the data using batch or stream processing to identify suspect code and metadata anomalies in the updated version. The engine may decompile executable binary code to obtain source code for the updated version and the prior version. A machine learning engine may receive input from the malicious software identification engine and classify the input using an NER-based machine learning model. Based on output from the machine learning engine, a control dashboard may block installation of a malicious product update.

Abstract: A compound useful as a host material in phosphorescent light emitting devices is disclosed.

Abstract: A compound having the formula (LA)mIr(LB)3-m, where LA is and LB is is disclosed. In the formula (LA)mIr(LB)3-m, LA and LB are different; each of X1 to X5 is C—RF or nitrogen; X is selected from O, S, and Se; each R1, R2, RB, RD, and RF is hydrogen or a substituent; R3 is alkyl, cycloalkyl, or a combination thereof; and m is 1 or 2. OLEDs, consumer products, and formulations including the compound are also disclosed.

Abstract: Organic compounds containing indolocarbazoles as electron donor connected with electron acceptors such aza-triphenylene or dibenzoquinoxaline that can improve the performance of phosphorescent organic light emitting devices are disclosed.

Abstract: A compound containing indolocarbazole having a formula: Formula I is disclosed.

Abstract: A composition is disclosed that includes a first compound capable of functioning as a host in an emissive layer of an OLED at room temperature; and a second compound that includes a ligand LA of Formula III where ring A is a 5-membered or 6-membered carbocyclic or heterocyclic ring; where R represents two adjacent substituents that are joined together to form a ring that is fused to ring B, and R has a structure of Formula IV or Formula V disclosed herein.

Abstract: Methods and reagents to obtaining a sample enriched in peptides comprising the third complementarity-determining region of the heavy chain (CDRH3) of immunoglobulins, such as IgGs, are described. These methods are based on the use of targeted protease digestion of immunoglobulins and affinity purification of CDRH3 peptides using specific antibodies. Such methods and reagents are useful for analyzing the immunoglobulin repertoire.

Abstract: A compound having a formula (LA)mIr(LB)3-m having a structure selected from is disclosed. In the structures of formula (LA)mIr(LB)3-m, m is 1 or 2, R1, R2, R3, R4, and R5 are each independently selected from hydrogen, deuterium, C1 to C6 alkyl, C1 to C6 cycloalkyl, and partially or fully deuterated variants thereof, and partially or fully fluorinated variants thereof, and, R6 is selected from C1 to C6 alkyl, C1 to C6 cycloalkyl, and partially or fully deuterated variants thereof, and partially or fully fluorinated variants thereof.

Abstract: A system for multi-factor user authentication for payment card-based transactions are described. The multifactor authentication may be based on a one-time passcode/password (OTP) as sent by an authentication server. A user device may, based on receiving the OTP, send an authentication code. The authentication code may be generated/determined based on the OTP. The authentication code may be augmented biometric identifier (ID) of a user associated with the user device. The authentication server may validate a transaction based on the authentication code.

Abstract: A system for multi-factor user authentication for payment card-based transactions are described. The multifactor authentication may be based on a one-time passcode/password (OTP) as sent by an authentication server. A user device may, based on receiving the OTP, send an authentication code. The authentication code may be generated/determined based on the OTP. The authentication code may be augmented biometric identifier (ID) of a user associated with the user device. The authentication server may validate a transaction based on the authentication code.

Abstract: A system for multi-factor user authentication for payment card-based transactions are described. The multifactor authentication may be based on a one-time passcode/password (OTP) as sent by an authentication server. A user device may, based on receiving the OTP, send an authentication code. The authentication code may be generated/determined based on the OTP. The authentication code may be augmented biometric identifier (ID) of a user associated with the user device. The authentication server may validate a transaction based on the authentication code.

Abstract: A compound comprising a ligand LA, having a structure of Formula I, is provided. In Formula I, A1 to A8 are each independently CR or N; at least two adjacent ones of A1 to A8 are CR and the Rs are joined together to form a six-membered ring fused to ring A or ring C; X is O, S, or Se; each R and RB is independently hydrogen or a substituent; any adjacent substituents are optionally joined or fused into a ring; the ligand LA is coordinated to a metal M; the metal M is bonded to ring A through a M-C bond; the metal M can be coordinated to other ligands; and the ligand LA is optionally linked with other ligands. Formulations, OLEDs, and consumer products containing such compounds are also disclosed.

Abstract: This invention discloses a novel two dimensional material having propellane core for organic light emitting diodes. These compounds can be used as hosts, charging transporting materials, or blocking materials for PHOLEDs. The devices comprising these compounds have better performance due to the honeycomb pi-extended structure in the propellane molecules.

Abstract: Provided are metalloorganic and organic compounds comprising a multicyclic system wherein a central nitrogen atom is part of two 5-membered rings which are fused together, and which are further fused together with three 6-membered aromatic rings. Also provided are formulations comprising these compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these compounds and compositions.

Abstract: Fluorine substituted metal complexes as efficient phosphorescent emitters is disclosed. The fluorine substitution is at para position of a phenyl group.

Abstract: A compound having the formula (LA)mIr(LB)3-m, where LA is and LB is selected from is disclosed. In the formula (LA)mIr(LB)3-m, LA and LB are different; each of X1 to X5 is C—RF or nitrogen; X is selected from O, S, and Se; each R1, R2, RB, RD, RE, and RF is hydrogen or a substituent; R3 is alkyl, cycloalkyl, or a combination thereof; and m is 1 or 2. OLEDs, consumer products, and formulations including the compound are also disclosed.

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Abstract: Provided are compounds of Formula (I?) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R8, R9, R11A, R11B, R12, Ri, Rii, A1, A2, Q1, Q2, Q3, X, W, and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.